VG2025

Phase 2Biologic

VVirogin Biotech Canada Ltd

VG2025 is one of 66 biologic programs targeting Advanced Malignant Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Malignant Solid TumorsRecruiting

Colorectal CancerNot yet recruiting

Advanced Malignant Solid TumorsPhase 1

Recruiting

Colorectal CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Stivarga

Bayer

Phase 3

39 2

Keytruda

Merck & Co.

Phase 3

25 3

Opdivo

Bristol-Myers Squibb

Phase 3

24 4

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

58 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

3 6

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Phase 3

4 7

5-Fu

TToray Industries, Inc

Phase 3

3 8

BL-M07D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 9

TQB2102

CChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 3

1 10

Calcium Levofolinate

FFujian Cancer Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Not yet recruiting

Colorectal Cancer

NCT07357220

Clinical

Trials by Indication[1]

Advanced Malignant Solid Tumors1 trial

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

Recruiting·VVirogin Biotech Canada Ltd·Phase 1·NCT05266612·12 enrolled

Colorectal Cancer1 trial

A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases

Not yet recruiting·AAkeso·Phase 1/2·NCT07357220·72 enrolled

Patients With Advanced Solid Tumors1 trial

Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT06365918

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for VG2025. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VG2025 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VG2025. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Virogin Biotech Canada Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: VVirogin Biotech Canada Ltd

VG2025

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Advanced Malignant Solid Tumors1 trial

Colorectal Cancer1 trial

Patients With Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News